Company intelligence / Profile preview
Kodiak Sciences
Palo Alto, California, United States of Americakodiak.com ↗
- Ownership
- Public · KOD
- Employees
- ~109
- Development stage
- Other
01
Overview
Kodiak Sciences has multiple programs in clinical development. Their lead candidate tarcocimab tedromer is in Phase 3 trials for wet AMD and diabetic retinopathy. KSI-501, a bispecific anti-IL-6/VEGF-trap antibody biopolymer conjugate, is in Phase 3 for wet AMD. KSI-101, an unconjugated bispecific protein, is in Phase 1b for macular edema secondary to inflammation.
- Therapeutic areas
- Ophthalmology
- Modalities
- Antibody Biopolymer ConjugatesBispecific antibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Nona BiosciencesLonza Group
Beyond the preview
Go deeper on Kodiak Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kodiak Sciences.